{"id":"https://openalex.org/W2113287405","doi":"https://doi.org/10.1530/eje-12-0167","title":"MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","display_name":"MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","alternate_titles":[],"publication_year":2012,"publication_date":"2012-04-10","ids":{"openalex":"https://openalex.org/W2113287405","doi":"https://doi.org/10.1530/eje-12-0167","mag":"2113287405","pmid":"https://pubmed.ncbi.nlm.nih.gov/22495490"},"language":"en","primary_location":{"id":"doi:10.1530/eje-12-0167","doi":"https://doi.org/10.1530/eje-12-0167","is_oa":true,"landing_page_url":"https://doi.org/10.1530/eje-12-0167","pdf_url":"https://eje.bioscientifica.com/downloadpdf/journals/eje/167/1/1.pdf","source":{"id":"https://openalex.org/S4210218062","display_name":"European Journal of Endocrinology","issn_l":"0804-4643","issn":["0804-4643","1479-683X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Endocrinology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2113287405"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://eje.bioscientifica.com/downloadpdf/journals/eje/167/1/1.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038131083","display_name":"Agata Juszczak","orcid":"https://orcid.org/0000-0002-1734-6388","observed_orcids":["https://orcid.org/0000-0002-1734-6388"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]},{"id":"https://openalex.org/I4210129944","display_name":"Oxford Centre for Diabetes, Endocrinology and Metabolism","ror":"https://ror.org/03myafa32","country_code":"GB","type":"facility","lineage":["https://openalex.org/I40120149","https://openalex.org/I4210129944","https://openalex.org/I4210147381"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Juszczak","raw_affiliation_strings":["Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, UK","institution_ids":["https://openalex.org/I40120149","https://openalex.org/I4210129944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108136401","display_name":"Avinash Gupta","orcid":"https://orcid.org/0009-0007-5889-0404","observed_orcids":["https://orcid.org/0009-0007-5889-0404"]},"institutions":[{"id":"https://openalex.org/I2801179840","display_name":"Churchill Hospital","ror":"https://ror.org/009vheq40","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801179840","https://openalex.org/I4210147381"]},{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Gupta","raw_affiliation_strings":["Department of Oncology, Churchill Hospital, University of Oxford, Oxford OX3 7LE, UK","NIHR Biomedical Research Centre, University of Oxford, Oxford OX3 7LE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Churchill Hospital, University of Oxford, Oxford OX3 7LE, UK","institution_ids":["https://openalex.org/I2801179840","https://openalex.org/I40120149"]},{"raw_affiliation_string":"NIHR Biomedical Research Centre, University of Oxford, Oxford OX3 7LE, UK","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079253584","display_name":"Niki Karavitaki","orcid":"https://orcid.org/0000-0002-4696-0643","observed_orcids":["https://orcid.org/0000-0002-4696-0643"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]},{"id":"https://openalex.org/I4210129944","display_name":"Oxford Centre for Diabetes, Endocrinology and Metabolism","ror":"https://ror.org/03myafa32","country_code":"GB","type":"facility","lineage":["https://openalex.org/I40120149","https://openalex.org/I4210129944","https://openalex.org/I4210147381"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Karavitaki","raw_affiliation_strings":["Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, UK","institution_ids":["https://openalex.org/I40120149","https://openalex.org/I4210129944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051430596","display_name":"Mark Ross Middleton","orcid":"https://orcid.org/0000-0003-0167-1685","observed_orcids":["https://orcid.org/0000-0003-0167-1685"]},"institutions":[{"id":"https://openalex.org/I2801179840","display_name":"Churchill Hospital","ror":"https://ror.org/009vheq40","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2801179840","https://openalex.org/I4210147381"]},{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. R. Middleton","raw_affiliation_strings":["Department of Oncology, Churchill Hospital, University of Oxford, Oxford OX3 7LE, UK","NIHR Biomedical Research Centre, University of Oxford, Oxford OX3 7LE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Churchill Hospital, University of Oxford, Oxford OX3 7LE, UK","institution_ids":["https://openalex.org/I2801179840","https://openalex.org/I40120149"]},{"raw_affiliation_string":"NIHR Biomedical Research Centre, University of Oxford, Oxford OX3 7LE, UK","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5046852415","display_name":"Ashley Barry Grossman","orcid":"https://orcid.org/0000-0003-1176-6186","observed_orcids":["https://orcid.org/0000-0003-1176-6186"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]},{"id":"https://openalex.org/I4210129944","display_name":"Oxford Centre for Diabetes, Endocrinology and Metabolism","ror":"https://ror.org/03myafa32","country_code":"GB","type":"facility","lineage":["https://openalex.org/I40120149","https://openalex.org/I4210129944","https://openalex.org/I4210147381"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"A. B. Grossman","raw_affiliation_strings":["Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, UK","institution_ids":["https://openalex.org/I40120149","https://openalex.org/I4210129944"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5046852415"],"corresponding_institution_ids":["https://openalex.org/I40120149","https://openalex.org/I4210129944"],"apc_list":{"value":3798,"currency":"EUR","value_usd":4292},"apc_paid":null,"fwci":10.6446,"has_fulltext":true,"cited_by_count":122,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.98929319,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"167","issue":"1","first_page":"1","last_page":"5"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10832","display_name":"Pituitary Gland Disorders and Treatments","score":0.7172999978065491,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10832","display_name":"Pituitary Gland Disorders and Treatments","score":0.7172999978065491,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.23989999294281006,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12421","display_name":"Adrenal Hormones and Disorders","score":0.016899999231100082,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/autoimmune-hypophysitis","display_name":"autoimmune hypophysitis","score":0.8859999775886536},{"id":"https://openalex.org/keywords/lymphocytic-hypophysitis","display_name":"lymphocytic hypophysitis","score":0.8980000019073486},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8429999947547913},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.8610000014305115},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.7480000257492065},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6679999828338623},{"id":"https://openalex.org/keywords/endocrine-disorders","display_name":"endocrine disorders","score":0.4620000123977661}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.9771729111671448},{"id":"https://openalex.org/C2780194577","wikidata":"https://www.wikidata.org/wiki/Q4120169","display_name":"Hypophysitis","level":4,"score":0.9326093196868896},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8510958552360535},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6634526252746582},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.5110477209091187},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5052230954170227},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4830056428909302},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.48044678568840027},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.47998544573783875},{"id":"https://openalex.org/C2780130043","wikidata":"https://www.wikidata.org/wiki/Q192360","display_name":"Autoimmunity","level":3,"score":0.43593108654022217},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41412603855133057},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4008522033691406},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.18555670976638794},{"id":"https://openalex.org/C2777658017","wikidata":"https://www.wikidata.org/wiki/Q156871","display_name":"Pituitary gland","level":3,"score":0.14885562658309937},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.11410015821456909},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.06721183657646179},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001327","descriptor_name":"Autoimmune Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D001327","descriptor_name":"Autoimmune Diseases","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007018","descriptor_name":"Hypopituitarism","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D007018","descriptor_name":"Hypopituitarism","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D013602","descriptor_name":"T-Lymphocytes, Cytotoxic","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1530/eje-12-0167","doi":"https://doi.org/10.1530/eje-12-0167","is_oa":true,"landing_page_url":"https://doi.org/10.1530/eje-12-0167","pdf_url":"https://eje.bioscientifica.com/downloadpdf/journals/eje/167/1/1.pdf","source":{"id":"https://openalex.org/S4210218062","display_name":"European Journal of Endocrinology","issn_l":"0804-4643","issn":["0804-4643","1479-683X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Endocrinology","raw_type":"journal-article"},{"id":"pmid:22495490","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22495490","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of endocrinology","raw_type":"Case Reports"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/ec7e821e-4851-4a94-9cb4-b8710f331bb1","doi":null,"is_oa":false,"landing_page_url":"https://research.birmingham.ac.uk/en/publications/ec7e821e-4851-4a94-9cb4-b8710f331bb1","pdf_url":null,"source":{"id":"https://openalex.org/S4306402634","display_name":"University of Birmingham Research Portal (University of Birmingham)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79619799","host_organization_name":"University of Birmingham","host_organization_lineage":["https://openalex.org/I79619799"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Juszczak, A, Gupta, A, Karavitaki, N, Middleton, M R & Grossman, A B 2012, 'Ipilimumab : a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review', European Journal of Endocrinology, vol. 167, no. 1, pp. 1-5. https://doi.org/10.1530/EJE-12-0167","raw_type":"article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.1005.9999","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.1005.9999","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://www.eje-online.org/content/early/2012/04/10/EJE-12-0167.full.pdf","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1530/eje-12-0167","doi":"https://doi.org/10.1530/eje-12-0167","is_oa":true,"landing_page_url":"https://doi.org/10.1530/eje-12-0167","pdf_url":"https://eje.bioscientifica.com/downloadpdf/journals/eje/167/1/1.pdf","source":{"id":"https://openalex.org/S4210218062","display_name":"European Journal of Endocrinology","issn_l":"0804-4643","issn":["0804-4643","1479-683X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Endocrinology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2113287405.pdf","grobid_xml":"https://content.openalex.org/works/W2113287405.grobid-xml"},"referenced_works_count":15,"referenced_works":["https://openalex.org/W1996617450","https://openalex.org/W2017347750","https://openalex.org/W2020727013","https://openalex.org/W2047185812","https://openalex.org/W2056085563","https://openalex.org/W2096060394","https://openalex.org/W2097995306","https://openalex.org/W2100127605","https://openalex.org/W2109465910","https://openalex.org/W2116169737","https://openalex.org/W2123363005","https://openalex.org/W2134638467","https://openalex.org/W2145308813","https://openalex.org/W2148576689","https://openalex.org/W4211068179"],"related_works":["https://openalex.org/W1475413520","https://openalex.org/W2888062196","https://openalex.org/W2319879075","https://openalex.org/W2323053538","https://openalex.org/W2209326243","https://openalex.org/W1523370243","https://openalex.org/W4389436566","https://openalex.org/W2768126425","https://openalex.org/W1767743048"],"abstract_inverted_index":{"Ipilimumab":[0],"(Yervoy;":[1],"Medarex":[2],"and":[3,25,86,131,161],"Bristol-Myers":[4],"Squibb)":[5],"is":[6,30],"a":[7,57,98,107,110],"human":[8],"MAB":[9],"against":[10],"cytotoxic":[11,19],"T-lymphocyte":[12],"antigen":[13],"4,":[14],"which":[15],"enhances":[16],"co-stimulation":[17],"of":[18,35,51,78,100,109,118,125,136,142,163],"T-lymphocytes,":[20],"resulting":[21],"in":[22,48,75,87,102,139],"their":[23],"proliferation":[24],"an":[26],"anti-tumour":[27],"response.":[28],"It":[29],"licensed":[31],"for":[32,127],"the":[33,49,76,134,140,148,152],"treatment":[34,50,160],"unresectable":[36],"or":[37],"metastatic":[38,128],"malignant":[39,129],"melanoma,":[40,130],"while":[41],"multiple":[42],"clinical":[43,58],"trials":[44],"using":[45],"this":[46],"medication":[47],"other":[52],"malignancies":[53],"are":[54,83],"ongoing.":[55],"As":[56],"response":[59],"to":[60,113,156],"ipilimumab":[61,126],"results":[62],"from":[63],"immunostimulation,":[64],"predictably":[65],"it":[66],"generates":[67],"autoimmunity":[68],"as":[69],"well,":[70],"causing":[71],"immune-related":[72],"adverse":[73],"events":[74],"majority":[77],"patients.":[79],"Of":[80],"those,":[81],"endocrinopathies":[82],"frequently":[84],"seen,":[85],"particular,":[88],"autoimmune":[89,165],"lymphocytic":[90,166],"hypophysitis":[91],"with":[92,116],"anterior":[93,119],"panhypopituitarism":[94,120],"has":[95],"been":[96],"reported":[97],"number":[99],"times":[101],"North":[103],"America.":[104],"We":[105,145],"present":[106],"case":[108,138],"male":[111],"referred":[112],"our":[114],"department":[115],"manifestations":[117],"after":[121],"his":[122,137],"third":[123],"dose":[124],"we":[132],"discuss":[133],"management":[135],"light":[141],"previous":[143],"reports.":[144],"also":[146],"review":[147],"published":[149],"literature":[150],"on":[151],"presenting":[153],"symptoms,":[154],"time":[155],"presentation,":[157],"investigations,":[158],"imaging,":[159],"follow-up":[162],"ipilimumab-induced":[164],"hypophysitis.":[167]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2113287405","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":12},{"year":2016,"cited_by_count":15},{"year":2015,"cited_by_count":20},{"year":2014,"cited_by_count":18},{"year":2013,"cited_by_count":17},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
